NUVB Nuvation Bio
- 2.960
- -0.120-3.90%
Nuvation Bio News
Wedbush: Reiterates the Nuvation Bio (NUVB.US) rating and adjusted from superior to superior market rating, with a target price of $5.00.
Wedbush: Reiterates the Nuvation Bio (NUVB.US) rating and adjusted from superior to superior market rating, with a target price of $5.00.
H.C. Wainwright Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $8
H.C. Wainwright analyst Robert Burns maintains $Nuvation Bio(NUVB.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 24.0% and a
HC Wainwright & Co. Reiterates Buy on Nuvation Bio, Maintains $8 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Nuvation Bio (NYSE:NUVB) with a Buy and maintains $8 price target.
Nuvation Bio GAAP EPS of -$0.07
Wedbush Reiterates Outperform on Nuvation Bio, Maintains $5 Price Target
Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and maintains $5 price target.
Buy Rating Justified by Nuvation Bio's Promising Drug Prospects and Strong Financials
Nuvation Bio (NUVB) Receives a Buy From RBC Capital
Nuvation Bio: A Strong Buy on Pipeline Promise and Financial Fortitude
Nuvation Bio (NUVB) Gets a Buy From TD Cowen
Nuvation Bio Q1 Loss Narrows; Shares Fall After Hours
Nuvation Bio (NUVB) reported a Q1 loss late Tuesday of $0.07 per diluted share, narrowing from the loss of $0.10 a year earlier. Analysts polled by Capital IQ expected a loss of $0.10. The company did
Nuvation Bio | 10-Q: Quarterly report
Nuvation Bio Q1 2024 Adj EPS $(0.07) Beats $(0.10) Estimate
Nuvation Bio (NYSE:NUVB) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by 30 percent.
Nuvation Bio 1Q Loss/Shr 7c >NUVB
Nuvation Bio 1Q Loss/Shr 7c >NUVB
Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update
Nuvation Bio Inc. (NYSE: NUVB), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial results for the first quarter ended March 31, 2024, and provided a business update.
Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 Inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Nuvation Bio Inc. (NYSE:NUVB), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that
Fifth Third Bancorp Reports Upbeat Earnings, Joins Metropolitan Bank Holding, Paramount Global And Other Big Stocks Moving Higher On Friday
U.S. stocks were mixed, with the Nasdaq Composite falling over 100 points on Friday.Shares of Fifth Third Bancorp (NASDAQ:FITB) rose during Friday's session after the company reported better-than-expe
Nuvation Bio Is Maintained at Outperform by RBC Capital
Nuvation Bio Is Maintained at Outperform by RBC Capital
Royal Bank of Canada: Maintaining the Nuvation Bio (NUVB.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $4.00 to $5.00.
Royal Bank of Canada: Maintaining the Nuvation Bio (NUVB.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $4.00 to $5.00.
RBC Capital Maintains Outperform on Nuvation Bio, Raises Price Target to $5
RBC Capital analyst Kennen MacKay maintains Nuvation Bio with a Outperform and raises the price target from $4 to $5.
Analysts Offer Insights on Healthcare Companies: Edgewise Therapeutics (EWTX), Healthequity (HQY) and Nuvation Bio (NUVB)
Analysis
Price Target
No Data
